Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk has a GLP-1 pill ... The company said that it manufactured about $500 million worth of pills, not one billion pills. When we learn of a mistake, we acknowledge it with a correction.

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

The announcement adds to a string of setbacks in Pfizer’s bid to win a slice of the booming market that Wall Street projects ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

A significant trial of a daily weight-loss pill has found that it helped people to shed the pounds and reduce their blood ...

Stock futures are little changed Wednesday night after a steep sell-off in the prior session. Futures tied to the Dow Jones ...

Several companies are developing weight-loss pills ... Novo Nordisk's Copenhagen-listed shares rose over 3%. Pfizer's shares rose about 1%, less than the 1.5% rise in the broader S&P 500 ...